Exploring two tumor treatment strategies: effectiveness of ribosome inactivating proteins and mesenchymal stem cells/MSC derived extracellular vesicles in cancer treatment DOI Creative Commons

Maryamosadat Mavaei,

Simin Farokhi,

Mohammad Hasan Yousefi

et al.

Frontiers in Oncology, Journal Year: 2025, Volume and Issue: 15

Published: May 13, 2025

Cancer is a complex and heterogeneous disease that often requires multifaceted treatment strategies to achieve optimal therapeutic outcomes. Given the limitations of single-agent therapies, particularly in face intricate biological signaling networks resistance, there growing need for combinatory approaches. This article presents novel hypothesis: simultaneous use ribosome-inactivating proteins (RIPs) mesenchymal stem cells (MSCs) or MSC-derived extracellular vesicles (EVs) cancer treatment. RIPs, with their potent cytotoxic properties, can target tumor effectively, while MSCs, known tumor-homing abilities regenerative potential, serve as delivery vehicles, potentially enhancing targeting precision reducing systemic toxicity RIPs. hypothesis explores synergistic potential combining these two modalities, leveraging advantages both techniques create more effective strategy. By RIPs’ ability inhibit protein synthesis MSCs EVs’ capability modulate microenvironment deliver agents. approach offers promising avenue overcoming cancer’s inherent complexity. However, challenges remain, such optimizing dosing protocols, addressing safety concerns, ensuring efficient drug delivery. Future research clinical trials are necessary validate this combination viable therapy.

Language: Английский

Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword DOI Creative Commons

Sina Kamrani,

Reza Naseramini,

Pouria Khani

et al.

Cancer Cell International, Journal Year: 2025, Volume and Issue: 25(1)

Published: March 26, 2025

Abstract Multiple myeloma (MM) is a hematological malignancy defined by the abnormal proliferation and accumulation of plasma cells (PC) within bone marrow (BM). While multiple impacts bone, it not classified as primary cancer. The microenvironment significantly influences progression its treatment response. Mesenchymal stromal (MSCs) in this environment engage with other components via direct contact secretion soluble factors. This review examines established roles MSCs facets MM pathology, encompassing their pro-inflammatory functions, contributions to tumor epigenetics, effects on immune checkpoint inhibitors (ICIs), influence reprogramming, chemotherapy resistance, senescence. investigates role development MM.

Language: Английский

Citations

0
Exploring two tumor treatment strategies: effectiveness of ribosome inactivating proteins and mesenchymal stem cells/MSC derived extracellular vesicles in cancer treatment DOI Creative Commons

Maryamosadat Mavaei,

Simin Farokhi,

Mohammad Hasan Yousefi

et al.

Frontiers in Oncology, Journal Year: 2025, Volume and Issue: 15

Published: May 13, 2025

Cancer is a complex and heterogeneous disease that often requires multifaceted treatment strategies to achieve optimal therapeutic outcomes. Given the limitations of single-agent therapies, particularly in face intricate biological signaling networks resistance, there growing need for combinatory approaches. This article presents novel hypothesis: simultaneous use ribosome-inactivating proteins (RIPs) mesenchymal stem cells (MSCs) or MSC-derived extracellular vesicles (EVs) cancer treatment. RIPs, with their potent cytotoxic properties, can target tumor effectively, while MSCs, known tumor-homing abilities regenerative potential, serve as delivery vehicles, potentially enhancing targeting precision reducing systemic toxicity RIPs. hypothesis explores synergistic potential combining these two modalities, leveraging advantages both techniques create more effective strategy. By RIPs’ ability inhibit protein synthesis MSCs EVs’ capability modulate microenvironment deliver agents. approach offers promising avenue overcoming cancer’s inherent complexity. However, challenges remain, such optimizing dosing protocols, addressing safety concerns, ensuring efficient drug delivery. Future research clinical trials are necessary validate this combination viable therapy.

Language: Английский

Citations

0